Emergent BioSolutions Inc.

NYSE:EBS

Biotechnology

Healthcare
$5.50 -2.58%

-$0.21 today

Market cap
$282.78M
Beta
2.33
P/E (TTM)
-47.9
EPS (TTM)
-$0.17
52W Low $5.62High $14.06

Volume 0.82M

Average 0.78M

EBS Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Emergent BioSolutions Inc.NYSE: EBS

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income declines year over year

Q1 FY2026 net income of $6.8M fell 90.0% year over year, ahead of the -93.5% change in trailing-twelve-month net income.

Context

  • Net income amounted to 7.1% of revenue in FY2025, down 11.2 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 2 analysts of $15.59M (-70.4%) for the fiscal year ending Dec 2026, a slowdown from the +127.6% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.8M+112.5% QoQ
Last fiscal yearDec 2025
$52.6M+127.6% YoY
LTMMar 2026
-$8.6M-93.5% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-90.0%-63.7%+26.3 pp
1 year+127.6%-70.4%-198.0 pp
3-year CAGR—+19.1%—
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
52.6M USD
Year-over-year change
+127.6%
4-year CAGR
-30.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How EBS compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -93.5% is the 10th highest of 11, against a peer median of +28.4%.
  • Net income amounts to 1.3% of revenue for EBS, versus a peer median of 21.6%.
EBS Competitors
Net Income for EBS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$364.23M USD+879.7%—121.5%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$185.15M USD+43.6%+15.7%—
CMPSCOMPASS Pathways plcLTM Mar 2026$178.8M USD+29.8%+46.5%—
PRTAProthena Corporation plcLTM Mar 2026$151.18M USD+37.1%+27.8%260.9%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$68.91M USD+27.1%+15.5%137.1%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$44.17M USD+6.7%-28.2%—
SIGASIGA Technologies, Inc.LTM Mar 2026$20.23M USD-58.3%-11.8%21.6%
SNDLSNDL Inc.LTM Mar 2026CA$10.98M CAD-89.7%-65.1%1.2%
EBSEmergent BioSolutions Inc.LTM Mar 2026$8.6M USD-93.5%—1.3%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$7.42M USD-95.2%-54.0%1.8%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$2.72M USD+117.1%+33.6%0.5%
Peer median (excluding EBS) —+28.4%+15.5%21.6%

Competitors are the stored peer set for EBS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income230.9M(211.6M)(760.5M)(190.6M)52.6M
Depreciation & Amortization123.8M143.3M125.1M108.8M95.8M
Deferred Income Tax46.9M(28.6M)(8.9M)(5.5M)(4M)
Stock-Based Compensation42.4M45.1M23.1M18M16.2M
Change in Working Capital(156.4M)(2.1M)(70.3M)88.7M(22.4M)
Accounts Receivables(48.2M)118.1M(21.6M)(24.4M)25.5M
Inventory(44M)(57.1M)600K(24.5M)(30.3M)
Accounts Payables(2.5M)(14M)10.6M(33M)(8.4M)
Other Working Capital(61.7M)(49.1M)(59.9M)170.6M(9.2M)
Other Non-Cash Items33.5M19.8M485.2M39.3M32.4M
Operating Cash Flow321.1M(34.1M)(206.3M)58.7M170.6M
Capital Expenditures(225M)(115.8M)(51.6M)(22.9M)(13.8M)
Acquisitions (Net)00270.2M00
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0(265.5M)(6.3M)148.1M83.2M
Investing Cash Flow(225M)(381.3M)212.3M125.2M69.4M
Debt Repayment(35.9M)564.2M(543.4M)(198.4M)(112.5M)
Common Stock Issued008.4M9.3M2.2M
Common Stock Repurchased(106M)(82.1M)00(24.9M)
Dividends Paid00000
Other Financing Activities900K(900K)(700K)(900K)(1.4M)
Financing Cash Flow(141M)481.2M(535.7M)(190M)(136.6M)
Effect of Forex Changes(300K)500K(1.2M)0100K
Net Change in Cash(45.2M)66.3M(530.9M)(6.1M)103.5M
Free Cash Flow96.1M(149.9M)(257.9M)35.8M156.8M

Emergent BioSolutions Inc.

NYSE:EBS

Intrinsic Alpha fair value

Locked

Current Price

$5.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.